Partner Headlines - EXEL

  1. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  2. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  3. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  4. Morning Market Movers

    Benzinga
  5. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  6. Benzinga's Top #PreMarket Gainers

    Benzinga
  7. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  8. Benzinga's Top #PreMarket Gainers

    Benzinga
  9. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  10. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  11. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  12. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  13. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  14. Stocks Hitting 52-Week Lows

    Benzinga
  15. Morning Market Losers

    Benzinga
  16. Benzinga's Top #PreMarket Losers

    Benzinga
  17. Morning Market Movers

    Benzinga
  18. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  19. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  20. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  21. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  22. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  23. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  24. US Stock Futures Up After Upbeat China Data

    Benzinga
  25. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  26. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  27. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  28. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  29. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  30. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  31. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  32. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  33. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  34. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  35. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  36. Health Care Sector Wrap

    FoxBusiness
  37. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  38. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  39. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  40. Exelixis Proposed Offering 20M Shares

    Benzinga
  41. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  42. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  43. Benzinga's Top Pre-Market Gainers

    Benzinga
  44. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  45. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  46. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  47. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  48. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  49. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  50. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  51. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  52. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  53. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  54. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  55. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  56. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  57. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  58. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  59. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  60. Notable Call Options Activity on Exelixis

    Benzinga
  61. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  62. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center